Clarity Pharmaceuticals (Clarity Pharmaceuticals) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Clarity Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Clarity Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Clarity Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

CLRPF' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 2 years, Clarity Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

CLRPF's Cash-to-Debt is ranked better than
99.74% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs CLRPF: No Debt

Clarity Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Clarity Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Clarity Pharmaceuticals Cash-to-Debt Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Cash-to-Debt

No Debt

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Clarity Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Clarity Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Cash-to-Debt falls into.

Clarity Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Clarity Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Clarity Pharmaceuticals had no debt ⁽¹⁾.

Clarity Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Clarity Pharmaceuticals had no debt ⁽¹⁾.

Clarity Pharmaceuticals (OTCPK:CLRPF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Clarity Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CU6:Australia

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.